CHRN

ChronoScale (operating as an exoskeleton maker — EksoNR, Ekso Indego, EVO) is in acute financial distress masquerading as a turnaround story. FY2025 revenue collapsed 29% to $12.8M — and crucially, the MD&A attributes this to a drop in Enterprise Health device volume in EMEA, the company's core revenue engine, only partially offset by Personal Health gains. The CMS reimbursement narrative for Ekso Indego Personal (approved April 2024 at ~$91,000) is the bull case, but two years in it has not arrested the top-line decline. Gross margin held at 53%, which is the only fundamental positive here.

The balance sheet is the dealbreaker. Cash fell 74% YoY to just $1.17M while operating cash burn was -$11.8M for FY2025. That is roughly five weeks of runway at the current burn rate, against $8.64M of current liabilities that grew 15% YoY even as total assets shrank 25%. Stockholders' equity of $9.0M is propped up by intangibles (the MD&A explicitly cites impairments on both an indefinite-lived trade name AND a finite-lived intangible during 2025) and sits atop a $262M accumulated deficit. Operating margin of -104% and ROE of -130% are not rounding errors — they describe a business that has never earned its cost of capital and is structurally unprofitable at current scale.